Influencia de los factores relacionados con el estado vascular periférico pretrasplante en el pronóstico funcional del trasplante renal

[ES]Los mecanismos por los que la Enfermedad Renal Crónica facilita el desarrollo de un envejecimiento prematuro del sistema vascular (afectando a las arterias coronarias, cerebrales y periféricas) son varios: por un lado la mayor prevalencia de factores de riesgo cardiovascular clásicos, por otra parte la elevada prevalencia de factores propios de la enfermedad renal crónica y por último los factores asociados al trasplante renal. En nuestro trabajo se exponen los resultados obtenidos tras investigar las variables relacionadas con arteriopatía periférica pretrasplante y su impacto en el pronóstico del injerto renal

Treatment with sotrovimab for SARS-CoV-2 infection in a cohort of high-risk kidney transplant recipients.

Sotrovimab is a neutralizing monoclonal antibody (mAb) that seems to remain active against recent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. The evidence on its use in kidney transplant (KT) recipients, however, is limited. We performed a multicenter, retrospective cohort study of 82 KT patients with SARS-CoV-2 infection {coronavirus disease 2019 [COVID-19]} treated with sotrovimab. Median age was 63 years. Diabetes was present in 43.9% of patients, and obesity in 32.9% of patients; 48.8% of patients had an estimated glomerular filtration rate under 30 mL/minute/1.73 m2. Additional anti-COVID-19 therapies were administered to 56 patients, especially intravenous steroids (65.9%). Sotrovimab was administered early ( Sotrovimab had an excellent safety profile, even in high-comorbidity patients and advanced chronic kidney disease stages. Earlier administration could prevent progression to severe disease, while clinical outcomes were poor in patients treated later. Larger controlled studies enrolling KT recipients are warranted to elucidate the true efficacy of monoclonal antibody therapies